Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis
Among adults 65 years and older, does high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against hospitalization and mortality compared with the standard dose?
Influenza Vaccine and Associated Infection and Death in California, 2024 to 2025
Among adults aged 65 years and older with laboratory confirmed influenza, vaccination was associated with 29% lower likelihood of death due to influenza-related causes.
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Updated analysis incorporating new evidence
HD-IIV remains cost-effective in Dutch adults aged ≥60.
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Comparing the Australian and New Zealand experiences in the evolving COVID-19 landscape highlights differences in policy and prescribing practice.
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
Eight vaccines linked to a lower risk of dementia
A growing body of research is beginning to reveal the impact that regular routine vaccines could be having on the likelihood of conditions like dementia.
European Medicines Agency (EMA) 2025 Annual Report
The report summarises EMA's work in evaluating and monitoring human and veterinary medicines, including approval numbers for 2025.